Genedrive PLC Initial overseas orders of MT-RNR1 ID kit (3761X)
20 December 2023 - 6:00PM
UK Regulatory
TIDMGDR
RNS Number : 3761X
Genedrive PLC
20 December 2023
genedrive plc
("genedrive" or the "Company")
Initial overseas orders of the Genedrive(R) MT-RNR1 ID Kit
genedrive plc (AIM: GDR), the point of care Pharmacogenetic
testing company, announces that initial orders of the Genedrive(R)
MT-RNR1 products have been received from France, Austria, Greece,
Saudi Arabia, Turkey and the Netherlands. This follows the Company
recently confirming that commercial distribution agreements for the
genedrive test for antibiotic induced hearing loss ("AIHL") in a
number of countries had been signed.
The initial orders will support genedrive's international
distribution partners in promotion and in-country evaluation
activities in their respective countries, to provide more extensive
access to this life-changing test.
James Cheek, Chief Executive Officer of genedrive plc, said: "We
are delighted to see the first orders come in from those countries
we have signed distribution agreements with. We look forward to the
continued expansion of our international sales throughout 2024 as
we drive forward with our sales and marketing strategies and
deliver value to our shareholders."
For further details, please contact:
genedrive plc +44 (0)161 989 0245
James Cheek: CEO / Russ Shaw: CFO
Peel Hunt LLP (Nominated Adviser
and Broker) +44 (0)20 7418 8900
James Steel / Patrick Birkholm
Walbrook PR Ltd (Media & Investor +44 (0)20 7933 8780 or genedrive@walbrookpr.com
Relations)
Anna Dunphy +44 (0)7876 741 001
About genedrive plc ( http://www.genedriveplc.com )
genedrive plc is a pharmacogenetic testing company developing
and commercialising a low cost, rapid, versatile, simple to use and
robust point of need pharmacogenetic platform for the diagnosis of
genetic variations. This helps clinicians to quickly access key
genetic information that will help them make the right choices over
the right medicine or dosage to use for an effective treatment.
Based in the UK, the Company is at the forefront of work on Point
of Care pharmacogenetics. Pharmacogenetics looks at how your
genetics impacts a medicines ability to work for you. Therefore, by
using pharmacogenetics, medicines can be made safer and more
effective. The Company has launched its flagship product, the
Genedrive(R) MT-RNR1 ID Kit, which is a single-use disposable
cartridge that circumvents the requirement for cold chain logistics
by providing temperature stable reagent test kits for use on their
proprietary test platform. This test allows clinicians to make a
decision on antibiotic use within 26 minutes; ensuring vital care
is delivered with no negative impact on the patient pathway.
The Company has a clear commercial strategy focused on
accelerating growth through maximising in-market sales, geographic
and portfolio expansion and strategic M&A, and operates out of
its facilities in Manchester.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFSTFLLALIV
(END) Dow Jones Newswires
December 20, 2023 02:00 ET (07:00 GMT)
Genedrive (LSE:GDR)
Historical Stock Chart
From Apr 2024 to May 2024
Genedrive (LSE:GDR)
Historical Stock Chart
From May 2023 to May 2024